Clinical trials
Unresectable Solid Tumor clinical trials
Below are recruiting unresectable solid tumor clinical trials, each written for real people, not researchers. We’re tracking 432 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06418061RecruitingPhase 1
Testing IBI3005 for advanced solid tumors
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
Jinan, ShandongAges 18 years+ - NCT07268040RecruitingPhase 2
Study of SHR-7787 injection plus other cancer drugs for solid tumors
This trial is testing a new drug, SHR-7787, combined with other cancer treatments for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07538479RecruitingPhase 1
Cold Exposure Plus Immunotherapy for Advanced Solid Tumors
This study tests whether controlled cold exposure combined with PD-1/PD-L1 immunotherapy (checkpoint inhibitor drugs that boost your immune system) can help fight solid tumors better than immunotherapy alone. The cold exposure is meant to trigger immune responses that may make the immunotherapy work more effectively.
Chengdu, SichuanAges 18–75 - NCT07362888RecruitingPhase 1
Testing a new drug ADCE-B05 for advanced solid tumors
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Springdale, ArkansasAges 18 years+ - NCT07327632RecruitingEarly Phase 1
Testing IBI3026 for advanced solid tumors
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
Chengdu, SichuanAges 18 years+ - NCT07181681RecruitingPhase 1
Study of BG-C0902 for advanced solid tumors
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
Houston, TexasAges 18 years+ - NCT05861895RecruitingPhase 1
Study drug HF158K1 for HER2-positive advanced solid tumors
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
Dallas, TexasAges 18–75 - NCT06727812RecruitingPhase 1
Testing a new targeted therapy for advanced solid tumors
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
Nanjing, JiangsuAges 18–75 - NCT07158918RecruitingPhase 1/Phase 2
Trial of ABL103 with pembrolizumab and chemo for advanced solid tumors
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Cleveland, OhioAges 18 years+ - NCT07382531RecruitingPhase 1/Phase 2
OH2 and BS006 injection for advanced solid tumors
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT06974812RecruitingPhase 1/Phase 2
Study of IBI3014 for advanced solid tumors
This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06088472RecruitingPhase 1
TIL therapy for advanced solid tumors
This trial tests a treatment made from your own immune cells (TILs) that are taken from a tumor, grown in a lab, and then given back to you to fight cancer. It's for people with solid tumors that have spread or come back after treatment.
Xuzhou, JiangsuAges 18–70 - NCT07228247RecruitingPhase 1/Phase 2
Study of HMPL-A251 for advanced HER2-positive cancers
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT06963281RecruitingPhase 1
Study of an experimental drug for late-stage solid tumors
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Pheonix, ArizonaAges 18–75 - NCT06241898RecruitingPhase 1
First study of a new drug for advanced solid tumors
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
Beijing, Beijing MunicipalityAges 18–78 - NCT07396584RecruitingPhase 1/Phase 2
HMPL-A580 for advanced or metastatic solid tumors
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Orange, CaliforniaAges 18 years+ - NCT05636215RecruitingPhase 1/Phase 2
Testing a new HER2-targeted drug for advanced solid tumors
This early-phase study tests a new investigational drug (IBI354) in people with advanced or metastatic solid cancers that have HER2 changes. It’s mainly meant to find out how the drug works in the body and whether it’s safe enough to keep studying.
Randwick, New South WalesAges 18 years+ - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT05978492RecruitingPhase 1
Study of TXN10128 for advanced solid tumors
This trial is testing a new drug, TXN10128, for people with advanced solid tumors that have stopped responding to other treatments. It may be an option if standard treatments haven't worked or aren't suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Unresectable Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable solid tumor?
- Yes. Clin2 currently lists 432 recruiting unresectable solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.